Use of botulinum toxin in the preventive and palliative treatment of the hips in children with infantile cerebral palsy

被引:6
|
作者
Pascual-Pascual, SI [1 ]
机构
[1] Hosp La Paz, Serv Neurol Pediat, Madrid, Spain
关键词
botulinum toxin; cerebral palsy; hip luxation; prevention and treatment; spasticity; spastic hip;
D O I
10.33588/rn.3701.2003225
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. The bilateral spastic cerebral palsy (CP) usually produces hip abnormalities, already presents in many cases before 2 years of age, whose diagnostic requires X-ray because clinical exam do not detect some of them. The prognosis of CP hip disorders with conventional treatment is had, progressive, and limits the possibility of independent gait. Botulin toxin type A infiltrated in adductors, medial ischiotibials and iliopsoas, in addition to physiotherapy and orthosis, gives better results. Patients, methods and results. In our cases (98 cases, 193 hips) the natural evolution before (BT-A) treatment had been of progressive lateral migration of femoral head (86% got worse, and 11,4% became luxated), and after the onset of it the progression stopped in 74% of hips and reverted in other 14%. Conclusions. It is very important to start early the BT-A treatment and infiltrate systematically every 3-4 months in order to obtain good results. Stopping the treatment increase the chances of subluxation or luxation. BT-A is also a good treatment for hip pain in spastic CP.
引用
收藏
页码:80 / 82
页数:3
相关论文
共 50 条
  • [1] Botulinum Toxin A in children with infantile cerebral palsy. Indications and treatment concepts
    Placzek, R.
    [J]. ORTHOPADE, 2010, 39 (01): : 23 - 30
  • [2] Use of botulinum toxin A in children with cerebral palsy
    Raftemo, Anne Elisabeth Ross
    Mahendran, Arani
    Hollung, Sandra Julsen
    Jahnsen, Reidun Birgitta
    Lydersen, Stian
    Vik, Torstein
    Andersen, Guro Lillemoen
    [J]. TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2019, 139 (08) : 713 - 717
  • [3] Botulinum toxin treatment in children with cerebral palsy
    Terebessy Tamas
    Domos Gyula
    Hever Dalma
    Horvath Nikoletta
    Kiss Sandor
    Szoke Gyorgy
    [J]. ORVOSI HETILAP, 2019, 160 (28) : 1105 - 1111
  • [4] Botulinum toxin A in the treatment of spasticity caused by infantile cerebral palsy
    Kanovsky, P
    Kraus, J
    Lnenicka, J
    [J]. CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 1998, 61 (05) : 261 - 266
  • [5] Development of Treatment Concepts for the Use of Botulinum Toxin A in Children with Cerebral Palsy
    Placzek, Richard
    Siebold, Dagmar
    Funk, Julia F.
    [J]. TOXINS, 2010, 2 (09) : 2258 - 2271
  • [6] Botulinum toxin Type A in infantile cerebral palsy
    不详
    [J]. PSYCHOPHARMAKOTHERAPIE, 2007, 14 (01): : X - X
  • [7] Use of botulinum toxin type A in children with cerebral palsy
    Nolan, KW
    Cole, LL
    Tak, GSL
    [J]. PHYSICAL THERAPY, 2006, 86 (04): : 573 - 584
  • [8] Use of botulinum toxin in 55 children with cerebral palsy
    Mohammadi, M
    [J]. CEREBRAL PALSY AT THE TURN OF THE MILLENNIUM, 2001, : 105 - 112
  • [9] Use of botulinum toxin A in management of children with cerebral palsy
    Friedman, Bat-Chen
    Goldman, Ran D.
    [J]. CANADIAN FAMILY PHYSICIAN, 2011, 57 (09) : 1006 - 1073
  • [10] Botulinum toxin in children with cerebral palsy
    Singhi P.
    Ray M.
    [J]. The Indian Journal of Pediatrics, 2004, 71 (12) : 1087 - 1091